Future Directions & Challenges in MM Precursor Conditions | María-Victoria Mateos, MD, PhD| IMS 2024

Future Directions & Challenges in MM Precursor Conditions | María-Victoria Mateos, MD, PhD| IMS 2024
Overall Survival with Cilta-cel vs Standard of Care in Lenalidomide Refractory MM | María-Victoria Mateos, MD, PhD | IMS 2024
Strategies used to Prevent T-cell Exhaustion in Myeloma | Hermann Einsele, MD, FRCP | IMS 2024
The Current Standard of Care in the Post-Transplant Setting | Fredrik Schjesvold, MD, PhD | IMS 2024
Risk Stratification for Smoldering Myeloma | Irene Ghobrial, MD | IMS 2024
Frontline Therapy in Multiple Myeloma | Claudio Cerchione, MD | IMS 2024
Diagnosis and Monitoring Multiple Myeloma | Claudio Cerchione, MD | IMS 2024
Preventing Multiple Myeloma | Claudio Cerchione, MD | IMS 2024
Defining High Risk Multiple Myeloma | Wee Joo Chng, MD, PhD | IMS 2024
Update on the iStopMM Study | Sigurður Kristinsson, MD, PhD | IMS 2024
CAR-T Therapy Trial for Relapsed/Refractory Acute Myeloid Leukemia

BETA - How is acute myeloid leukemia diagnosed?
Phase 3 Trials & Quadruplet Therapy in Newly Diagnosed Multiple Myeloma | Bruno Costa, MD | IMS 2024
Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024
Real World Data on Ide-Cel Efficacy and Side Effects Profile | Rafat Abonour, MD | IMS 2024
Efficacy of Bispecifics in Black Patients in Myeloma Trials | Craig Emmitt Cole, MD | IMS 2024